On December 9, 2024, Shanghai Fosun Pharma (Group) Co., Ltd. repurchased 0.306 million H shares on the Hong Kong Stock Exchange, accounting for 0.06% of the company's total issued H shares. The repurchase price range was HKD 14.1 to HKD 14.5, with a total amount of HKD 4.3636 million.The repurchased shares will be held as treasury shares, increasing the company's treasury shares to 6.64 million shares. This repurchase was authorized at the shareholder meeting on June 26, 2024, allowing the company to repurchase up to 55.1941 million H shares. Following this repurchase, the company has accumulated 1.2% of the authorized quota.According to relevant regulations, the company is not allowed to issue new shares or sell or transfer treasury shares within 30 days after this repurchase (i.e., before January 8, 2025), unless approved by the Hong Kong Stock Exchange.

On December 9, 2024, Shanghai Fosun Pharma (Group) Co., Ltd. repurchased 0.306 million H shares on the Hong Kong Stock Exchange, accounting for 0.06% of the company's total issued H shares. The repurchase price range was HKD 14.1 to HKD 14.5, with a total amount of HKD 4.3636 million.The repurchased shares will be held as treasury shares, increasing the company's treasury shares to 6.64 million shares. This repurchase was authorized at the shareholder meeting on June 26, 2024, allowing the company to repurchase up to 55.1941 million H shares. Following this repurchase, the company has accumulated 1.2% of the authorized quota.According to relevant regulations, the company is not allowed to issue new shares or sell or transfer treasury shares within 30 days after this repurchase (i.e., before January 8, 2025), unless approved by the Hong Kong Stock Exchange.